Advertisement

Topics

Gilead announces FDA priority review designation for fixed-dose treatment of HIV

13:55 EDT 11 Aug 2017 | CentreWatch

Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI) and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead filed […]

The post Gilead announces FDA priority review designation for fixed-dose treatment of HIV appeared first on CenterWatch News Online.

Original Article: Gilead announces FDA priority review designation for fixed-dose treatment of HIV

NEXT ARTICLE

More From BioPortfolio on "Gilead announces FDA priority review designation for fixed-dose treatment of HIV"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...